Inside this Issue |
It’s Time to Celebrate!Throughout the past 25 years, SITC has brought together the top experts and best science, collaborated with world-wide partners, guided progress, advanced careers, shaped discussions, and shared joint success! We invite you to attend the 25th Annual Meeting & Programs to celebrate with us - 25 years of innovative science and a future of successes in the biological/immunotherapy field! Join us October 1-4, 2010 in Washington, D.C.!
 In celebration of SITC’s 25 years, we’re adding some special features and activities to the 2010 programs. Watch for more details on the website and in email. Share your SITC photos and memories! |
Free Webinar!
Global Regulatory Summit: Considerations in the Development of Oncology Biologics Products for the Treatment of Cancer
Did you miss it? Want to see it again or know a colleague who’d be interested?
Check it out today:
This free webinar is available on the SITC website and features insight on regulatory agency protocols and requirements as presented by representatives from:
- U.S. Food and Drug Administration (FDA)
- European Medicines Agency
- Japan Science and Technology Agency
- Pharmaceuticals and Medical Devices Agency, Japan
- Center for Drug Evaluation, SFDA, P.R. China
- Paul-Ehrlich-Institut, Germany
- Department of Biotechnology, Government of India
- Health Canada
Their multiple perspectives provide a comprehensive view of the regulatory pathways available to those who are involved in clinical trials in the area of oncology biologics product development. Viewers will understand key regulatory challenges, be able to identify immunological endpoints in pre-clinical and clinical studies, and better understand and appreciate the requirements for accelerated approval or conditional marketing authorization for promising new biologics.
Thanks to the SITC Trust Donors
SITC thanks the inaugural donors who helped successfully launch the SITC Trust.
Established in 2009, the goals of the Trust are to support research, training, and education in the field of cancer immunotherapy/biological therapy.
Through purchasing and wearing “Friends of the President” ribbons at the 2009 Annual Meeting, donors honored President Bernie Fox and showed their special commitment to the field.
Thank you!
To support the trust in 2010, purchase a “Friend of the President” ribbon on your meeting registration form or contact the SITC office.
SITC Goes Open Access! The NEW Journal Subsection
SITC is excited to announce its collaboration with the Journal of Translational Medicine in the formation of a new journal subsection titled "Tumor Immunology and Biological Cancer Therapy," edited by SITC. This subsection will complement the society’s official journal, Journal of Immunotherapy, by offering rapid publication of additional topics in biological therapy in an open-access format.
Through open-access, all articles published in the online subsection will be available and accessible to the public free of charge. In keeping with SITC’s mission of discussing and disseminating the lastest research, a discussion feature is also available for providing comments on articles.
Both SITC Members and non-members are encouraged to submit manuscripts for review and inclusion in the subsection. SITC members also receive discounted submission fees.
Longtime member and past Board of Directors member, Pedro J. Romero, MD from the Ludwig Institute for Cancer Research brings his enthusiasm and expertise to the position of Editor-in-Chief of the new subsection.
Check out SITC’s new subsection "Tumor Immunology and Biological Cancer Therapy" and read the mission and goals editorial written by Dr. Romero and SITC President Bernie Fox, PhD.
Member Spotlight: Pedro J. Romero, MD
We asked Dr. Pedro J. Romero, editor of SITC's "Tumor Immunology and Biological Cancer Therapy" subsection of the Journal of Translational Medicine to tell us more about himself and the new open-access subsection.
Q: As the Editor of the SITC subsection, what is your main goal?
A: We’d like to enrich the communication between basic biological and immunological sciences and the clinical investigation arena.
Q: Why was the section created?
A: With the latest advances, the immunotherapy/biological therapy community as a whole is now oriented toward the prospect of identifying combination anti-cancer therapies that may reach unmatched clinical efficacy. Such levels of activity require appropriate means to share new knowledge and to catalyze the development of the field. This section aims to provide such a platform.
Q: What role does SITC play in the global immunotherapy/biological therapy community?
A: The Society has become one of the most important vehicles available to the community for networking and the timely sharing of research results. The SITC plays a very important role in bringing together basic scientists, clinicians and industry. In recent years, the Society has also effectively advocated for increased attention to immunotherapy and biological therapy of cancer with funding bodies and regulatory authorities.
Q: How does being a member of SITC help you? What do you like about SITC?
A: I regularly find that attending the Annual Meeting is very helpful. Cutting edge scientific content, workshops with the leading experts, and the hot topics sessions are great opportunities to catch up with the latest results and news. Moreover, being a member of the SITC provides invaluable opportunities to establish contacts and even initiate scientific collaborations.
Read the full mission and goals editorial written by Dr. Romero and SITC President Bernie Fox, PhD.
New Board Members
Election results are in and we are pleased to announce the addition of three new members to the SITC Board of Directors. We are grateful for their contribution to the society and wish them the best of luck serving in leadership positions through 2012. New members include:
- F. Stephen Hodi, MD - Dana-Farber Cancer Institute
- Howard Kaufman, MD - Rush University Medical Center
- William J. Murphy, PhD - University of California at Davis
Bylaws Revisions
Revisions to the bylaws were also approved at the Annual Meeting. For a complete copy of the SITC Bylaws, visit the SITC website. Notable changes to the bylaws include:
- Editors of any affiliated journals will be ex-officio (non-voting) members of the Board.
- Eligibility for officer positions on the board has been changed to include anyone who has previously served a full board term and is in good standing.
- Timing of expiring terms for past board members was clarified for Executive Council eligibility.
Invite to Supporters & Exhibitors
Want to identify your company as an innovator and thought leader in the global biological/immunotherapy community?
Contact the SITC office for marketing and educational support opportunities available in conjunction with the 2010 programs.